Regenera Pharma Overview
- Year Founded
-
2008
- Status
-
Out of Business
- Employees
-
6
- Latest Deal Type
-
Out of Business
Regenera Pharma General Information
Description
Operator of a clinical-stage pharmaceutical company intended to develop drugs and other related pharmaceutical products. The company's drugs are used to treat neurological damage caused by pathological conditions and regenerating damaged tissues, enabling patients to avail drugs for neurodegenerative diseases and chronic non-healing wounds, providing patients to restore neural function.
Contact Information
Website
www.regenerapharma.comCorporate Office
- Einstein 18, Science Park
- Ness Ziona
- Israel
Corporate Office
- Einstein 18, Science Park
- Ness Ziona
- Israel
Regenera Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Out of Business | 20-Apr-2021 | Completed | Out of Business | |||
| 5. Later Stage VC (Series B) | 02-Jan-2018 | Completed | Generating Revenue | |||
| 4. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 3. Later Stage VC | 17-Feb-2015 | Completed | Generating Revenue | |||
| 2. Angel (individual) | 01-Jan-2012 | $400K | $1.02M | Completed | Startup | |
| 1. Angel (individual) | 01-Jan-2011 | $625K | $625K | Completed | Startup |
Regenera Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferred B2 | ||||||||
| Preferred B1 | ||||||||
| Preferred B | ||||||||
| Preferred A1 | 1,412,071 | $0.010000 | $5.75 | $5.75 | 1x | $5.75 | 2.78% | |
| Preferred A | 1,412,071 | $0.010000 | $4.6 | $4.6 | 1x | $4.6 | 21.24% |
Regenera Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Regenera Pharma Patents
Regenera Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20190224217-A1 | Compositions comprising triterpenoids and uses thereof for treating optic neuropathy | Active | 08-Sep-2016 | ||
| US-11207333-B2 | Compositions comprising triterpenoids and uses thereof for treating optic neuropathy | Active | 08-Sep-2016 | ||
| EP-3509699-A1 | Compositions comprising triterpenoids and uses thereof for treating optic neuropathy | Pending | 08-Sep-2016 | ||
| US-20190224216-A1 | Compositions comprising acidic extracts of mastic gum and uses thereof for treating optic neuropathy | Active | 08-Sep-2016 | ||
| EP-3509577-A1 | Compositions comprising acidic extracts of mastic gum and uses thereof for treating optic neuropathy | Pending | 08-Sep-2016 | A61K31/568 |
Regenera Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Regenera Pharma FAQs
-
When was Regenera Pharma founded?
Regenera Pharma was founded in 2008.
-
Where is Regenera Pharma headquartered?
Regenera Pharma is headquartered in Ness Ziona, Israel.
-
What is the size of Regenera Pharma?
Regenera Pharma has 6 total employees.
-
What industry is Regenera Pharma in?
Regenera Pharma’s primary industry is Biotechnology.
-
Is Regenera Pharma a private or public company?
Regenera Pharma is a Private company.
-
What is Regenera Pharma’s current revenue?
The current revenue for Regenera Pharma is .
-
How much funding has Regenera Pharma raised over time?
Regenera Pharma has raised $24.7M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
